BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37288720)

  • 1. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
    Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
    Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.
    Oksenhendler E; Boulanger E; Galicier L; Du MQ; Dupin N; Diss TC; Hamoudi R; Daniel MT; Agbalika F; Boshoff C; Clauvel JP; Isaacson PG; Meignin V
    Blood; 2002 Apr; 99(7):2331-6. PubMed ID: 11895764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.
    Pria AD; Pinato D; Roe J; Naresh K; Nelson M; Bower M
    Blood; 2017 Apr; 129(15):2143-2147. PubMed ID: 28143881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
    Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
    Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression.
    Lin IF; Lin JN; Tsai TH; Hsu CT; Wu YY; Lai CH
    Int J STD AIDS; 2021 Mar; 32(3):286-289. PubMed ID: 33555231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
    Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
    Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
    Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
    Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
    Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
    Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma?
    Sayer R; Paul J; Tuke PW; Hargreaves S; Noursadeghi M; Tedder RS; Grant P; Edwards SG; Miller RF
    Int J STD AIDS; 2011 Oct; 22(10):585-9. PubMed ID: 21998180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence.
    Darwish I; Costiniuk C; Kronfli N; Haegert D; Routy JP
    IDCases; 2021; 26():e01315. PubMed ID: 34786336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.
    Kaga H; Kurahashi H; Kubota A; Hatano Y; Nanjo H; Wakui H; Takahashi N
    Int J Hematol; 2022 Jan; 115(1):129-134. PubMed ID: 34591291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation.
    Hogan LE; Hanhauser E; Hobbs KS; Palmer CD; Robles Y; Jost S; LaCasce AS; Abramson J; Hamdan A; Marty FM; Kuritzkes DR; Henrich TJ
    PLoS One; 2018; 13(5):e0197298. PubMed ID: 29746555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.
    Gopal S; Liomba NG; Montgomery ND; Moses A; Kaimila B; Nyasosela R; Chikasema M; Dhungel BM; Kampani C; Sanders MK; Krysiak R; Dittmer DP; Fedoriw Y
    J Int AIDS Soc; 2015; 18(1):20122. PubMed ID: 26242311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
    Law AB; Ryan G; Lade S; Prince HM
    Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
    Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
    Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection: A case report.
    Guayboon T; Chinthammitr Y; Sukpanichnant S; Horthongkham N; Angkasekwinai N
    Medicine (Baltimore); 2021 Dec; 100(49):e28077. PubMed ID: 34889256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
    Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
    Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.
    Nagao A; Nakazawa S; Hanabusa H
    J Hematol Oncol; 2014 Jan; 7():10. PubMed ID: 24438824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?
    Alkaied H; Harris K; Elsayegh D; Khachaturova I; Awasum M; Varma S
    Med Oncol; 2012 Jun; 29(2):1109-13. PubMed ID: 21472488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab therapy for HIV-associated Castleman disease.
    Marcelin AG; Aaron L; Mateus C; Gyan E; Gorin I; Viard JP; Calvez V; Dupin N
    Blood; 2003 Oct; 102(8):2786-8. PubMed ID: 12842986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.